The Claim
In older adults with coronary artery disease undergoing cardiac rehabilitation, daily administration of low-dose oral rapamycin (0.5–1.0 mg) over 12 weeks was associated with a reduction in serum interleukin-6 levels from 4.4 to 2.6 pg/ml, suggesting a potential modulation of systemic inflammation related to cellular senescence.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Older adults with heart disease who took a low dose of a drug called rapamycin every day for 12 weeks saw their inflammation levels go down, which might help slow aging-related damage in the body.
See the scientific wording
In older adults with coronary artery disease undergoing cardiac rehabilitation, daily low-dose oral rapamycin (0.5–1.0 mg) for 12 weeks was associated with reduced serum interleukin-6 levels (from 4.4 to 2.6 pg/ml), suggesting a potential modulation of systemic inflammation linked to cellular senescence.
What the research says
1 studyThe study gave low-dose rapamycin to older heart patients and found that inflammation in their blood went down, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.